London: Merck said on Thursday its therapy did not meet the main goal of disease-free survival in certain patients with endometrial cancer during a late-stage trial.
The drugmaker’s Keytruda therapy in combination with chemotherapy was being evaluated in patients with high-risk endometrial cancer after surgery.
The study’s other main goal of overall survival was not formally tested since the trial failed in showing significant disease-free survival.
Endometrial cancer begins in the inner lining of the uterus, or endometrium, and is the most common type of the disease affecting the organ.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta and Shilpi Majumdar)
